A practical reference on lyophilized powder: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-22. Anything still debated is marked as such rather than presented as settled.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
The white shark is the sole living species in the genus Carcharodon and is one of five living species of the family Lamnidae. The other four members of this family are the mako sharks, porbeagle, and salmon shark. The family belongs to the Lamniformes, the order of mackerel sharks. The white shark first appears in the fossil record in the Pacific basin around 6–5 mya, between the late Miocene and early Pliocene. Like all sharks, the white shark's skeleton is made primarily of soft cartilage that does not preserve well. As a result, the overwhelming majority of fossils are teeth. Nevertheless, paleontologists have traced the emergence of the white shark and its immediate ancestry to a large extinct shark known as Carcharodon hastalis. This species had teeth similar to the modern white shark's, except for the cutting edges, which lacked serrations. C. hastalis occupied a similar position in the food web to modern white sharks and was probably mostly fish-eating, with some marine mammals in its diet, though its lack of serrations made it a less efficient predator of them. Around 8–6 mya, a Pacific population of C. hastalis evolved into C. hubbelli. This divergent lineage was characterized by a gradual development of serrations over the next few million years. Teeth from the same time period may exhibit significant variation in shape and their serrations, which may be indicative of persistent interbreeding with C. hastalis for at least some time. White sharks descended from C.
By 1959, the average weight was around 12 kg (today, chainsaws typically weigh between 4 and 5 kg, with heavy-duty models ranging from 7 to 9 kg), and it quickly gained attention. McCulloch in North America started to produce chainsaws in 1948. The early models were heavy, two-person devices with long bars. Often, chainsaws were so heavy that they had wheels like dragsaws. Other outfits used driven lines from a wheeled power unit to drive the cutting bar. Carburettors featuring swivel and floating diaphragms were developed after the war, enabling modern chainsaws to operate in any orientation without the risk of flooding or fuel starvation. Additionally, the use of lighter materials played a crucial role in the advancement of the modern hand-held chainsaw. Logging operations use a variety of these specialized machinery, but hand felling with a cable skidder (where tractors and horses may still be utilized) continues to be a viable, cost-effective way to make a living as a logger. They are made in many sizes, from small electric saws intended for home and garden use, to large "lumberjack" saws. Members of military engineer units are trained to use chainsaws, as are firefighters to fight forest fires and to ventilate structure fires. Three main types of chainsaw sharpeners are used: handheld file, electric chainsaw, and bar-mounted. The first electric chainsaw was invented by Stihl in 1926.
Such machines are used for freezing oocytes, skin, blood products, embryo, sperm, stem cells, and general tissue preservation in hospitals, veterinary practices, and research labs. The number of live births from 'slow frozen' embryos is some 300,000 to 400,000 or 20% of the estimated 3 million in vitro fertilized births. Dr Christopher Chen, Australia, reported the world’s first pregnancy using slow-frozen oocytes from a British controlled-rate freezer in 1986. Cryosurgery (intended and controlled tissue destruction by ice formation) was carried out by James Arnott in 1845 in an operation on a patient with cancer.
=== EC 2.5.1: Transferring alkyl or aryl groups, other than methyl groups (only sub-subclass identified to date) === EC 2.5.1.1: dimethylallyltranstransferase EC 2.5.1.2: thiamine pyridinylase EC 2.5.1.3: thiamine-phosphate diphosphorylase EC 2.5.1.4: Now EC 4.4.1.42 adenosylmethionine cyclotransferase EC 2.5.1.5: galactose-6-sulfurylase EC 2.5.1.6: methionine adenosyltransferase EC 2.5.1.7: UDP-N-acetylglucosamine 1-carboxyvinyltransferase EC 2.5.1.8: transferred to EC 2.5.1.75, tRNA dimethylallyltransferase EC 2.5.1.9: riboflavin synthase EC 2.5.1.10: (2E,6E)-farnesyl diphosphate synthase EC 2.5.1.11: Now covered by EC 2.5.1.84 (all-trans-nonaprenyl-diphosphate synthase [geranyl-diphosphate specific]) and EC 2.5.1.85 (all-trans-nonaprenyl diphosphate synthase [geranylgeranyl-diphosphate specific]) EC 2.5.1.12: deleted, now included with EC 2.5.1.18 glutathione transferase EC 2.5.1.13: deleted, now included with EC 2.5.1.18 glutathione transferase EC 2.5.1.14: deleted, now included with EC 2.5.1.18 glutathione transferase EC 2.5.1.15: dihydropteroate synthase EC 2.5.1.16: spermidine synthase EC 2.5.1.17: cob(I)yrinic acid a,c-diamide adenosyltransferase EC 2.5.1.18: glutathione transferase EC 2.5.1.19: 3-phosphoshikimate 1-carboxyvinyltransferase EC 2.5.1.20: rubber cis-polyprenylcistransferase EC 2.5.1.21: squalene synthase EC 2.5.1.22: spermine synthase EC 2.5.1.23: sym-norspermidine synthase EC 2.5.1.24: discadenine synthase EC 2.5.1.25: tRNA-uridine aminocarboxypropyltransferase EC 2.5.1.26: alkylglycerone-phosphate synthase EC 2.5.1.27: adenylate dimethylallyltransferase EC 2.5.1.28: dimethylallylcistransferase EC 2.5.1.29: farnesyltranstransferase EC 2.5.1.30: trans-hexaprenyltranstransferase EC 2.5.1.31: ditrans,polycis-undecaprenyl-diphosphate synthase [(2E,6E)-farnesyl-diphosphate specific] EC 2.5.1.32: 15-cis-phytoene synthase EC 2.5.1.33: deleted, now covered by EC 2.5.1.82 hexaprenyl diphosphate synthase [geranylgeranyl-diphosphate specific] and EC 2.5.1.83 hexaprenyl diphosphate synthase [(2E,6E)-farnesyl-diphosphate specific] EC 2.5.1.34: tryptophan dimethylallyltransferase EC 2.5.1.35: aspulvinone dimethylallyltransferase EC 2.5.1.36: trihydroxypterocarpan dimethylallyltransferase EC 2.5.1.37: Now EC 4.4.1.20, leukotriene-C4 synthase EC 2.5.1.38: isonocardicin synthase EC 2.5.1.39: 4-hydroxybenzoate polyprenyltransferase EC 2.5.1.40: Now EC 4.2.3.9, aristolochene synthase EC 2.5.1.41: phosphoglycerol geranylgeranyltransferase EC 2.5.1.42: geranylgeranylglycerol-phosphate geranylgeranyltransferase EC 2.5.1.43: nicotianamine synthase EC 2.5.1.44: homospermidine synthase EC 2.5.1.45: homospermidine synthase (spermidine-specific) EC 2.5.1.46: deoxyhypusine synthase EC 2.5.1.47: cysteine synthase EC 2.5.1.48: cystathionine γ-synthase EC 2.5.1.49: O-acetylhomoserine aminocarboxypropyltransferase EC 2.5.1.50: zeatin 9-aminocarboxyethyltransferase EC 2.5.1.51: β-pyrazolylalanine synthase EC 2.5.1.52: L-mimosine synthase EC 2.5.1.53: uracilylalanine synthase EC 2.5.1.54: 3-deoxy-7-phosphoheptulonate synthase EC 2.5.1.55: 3-deoxy-8-phosphooctulonate synthase EC 2.5.1.56: N-acetylneuraminate synthase EC 2.5.1.57: N-acylneuraminate-9-phosphate synthase EC 2.5.1.58: protein farnesyltransferase EC 2.5.1.59: protein geranylgeranyltransferase type I EC 2.5.1.60: protein geranylgeranyltransferase type II EC 2.5.1.61: hydroxymethylbilane synthase EC 2.5.1.62: chlorophyll synthase EC 2.5.1.63: adenosyl-fluoride synthase EC 2.5.1.64: The reaction that was attributed to this enzyme is now known to be catalysed by two separate enzymes: EC 2.2.1.9 2-succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-carboxylic-acid synthase and EC 4.2.99.20 2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylate synthase EC 2.5.1.65: O-phosphoserine sulfhydrylase EC 2.5.1.66: N2-(2-carboxyethyl)arginine synthase EC 2.5.1.67: chrysanthemyl diphosphate synthase EC 2.5.1.68: (2Z,6E)-farnesyl diphosphate synthase EC 2.5.1.69: lavandulyl diphosphate synthase EC 2.5.1.70: naringenin 8-dimethylallyltransferase EC 2.5.1.71: leachianone-G 2′′-dimethylallyltransferase EC 2.5.1.72: quinolinate synthase EC 2.5.1.73: O-phospho-L-seryl-tRNA:Cys-tRNA synthase EC 2.5.1.74: 1,4-dihydroxy-2-naphthoate polyprenyltransferase EC 2.5.1.75: tRNA dimethylallyltransferase EC 2.5.1.76: cysteate synthase EC 2.5.1.77: Now EC 2.5.1.147, 5-amino-6-(D-ribitylamino)uracil—L-tyrosine 4-methylphenol transferase and EC 4.3.1.32, 7,8-didemethyl-8-hydroxy-5-deazariboflavin synthase. EC 2.5.1.78: 6,7-dimethyl-8-ribityllumazine synthase EC 2.5.1.79: thermospermine synthase EC 2.5.1.80: 7-dimethylallyltryptophan synthase EC 2.5.1.81: geranylfarnesyl diphosphate synthase EC 2.5.1.82: hexaprenyl diphosphate synthase [geranylgeranyl-diphosphate specific] EC 2.5.1.83: hexaprenyl diphosphate synthase [(2E,6E)-farnesyl-diphosphate specific] EC 2.5.1.84: all-trans-nonaprenyl-diphosphate synthase (geranyl-diphosphate specific) EC 2.5.1.85: all-trans-nonaprenyl diphosphate synthase [geranylgeranyl-diphosphate specific] EC 2.5.1.86: trans,polycis-decaprenyl diphosphate synthase EC 2.5.1.87: ditrans,polycis-polyprenyl diphosphate synthase [(2E,6E)-farnesyl diphosphate specific] EC 2.5.1.88: trans,polycis-polyprenyl diphosphate synthase [(2Z,6E)-farnesyl diphosphate specific] EC 2.5.1.89: tritrans,polycis-undecaprenyl diphosphate synthase [geranylgeranyl-diphosphate specific] EC 2.5.1.90: all-trans-octaprenyl-diphosphate synthase EC 2.5.1.91: all-trans-decaprenyl-diphosphate synthase EC 2.5.1.92: (2Z,6Z)-farnesyl diphosphate synthase EC 2.5.1.93: 4-hydroxybenzoate geranyltransferase EC 2.5.1.94: adenosyl-chloride synthase EC 2.5.1.95: xanthan ketal pyruvate transferase EC 2.5.1.96: 4,4′-diapophytoene synthase EC 2.5.1.97: pseudaminic acid synthase EC 2.5.1.98: Rhizobium leguminosarum exopolysaccharide glucosyl ketal-pyruvate-transferase EC 2.5.1.99: The activity was an artifact caused by photoisomerization of the product of EC 2.5.1.32, 15-cis-phytoene synthase EC 2.5.1.100: fumigaclavine A dimethylallyltransferase EC 2.5.1.101: N,N′-diacetyllegionaminate synthase EC 2.5.1.102: geranyl-pyrophosphate—olivetolic acid geranyltransferase EC 2.5.1.103: presqualene diphosphate synthase EC 2.5.1.104: N1-aminopropylagmatine synthase EC 2.5.1.105: 7,8-dihydropterin-6-yl-methyl-4-(β-D-ribofuranosyl)aminobenzene 5′-phosphate synthase EC 2.5.1.106: tryprostatin B synthase EC 2.5.1.107: verruculogen prenyltransferase EC 2.5.1.108: 2-(3-amino-3-carboxypropyl)histidine synthase EC 2.5.1.109: brevianamide F prenyltransferase (deoxybrevianamide E-forming) EC 2.5.1.110: 12α,13α-dihydroxyfumitremorgin C prenyltransferase EC 2.5.1.111: 4-hydroxyphenylpyruvate 3-dimethylallyltransferase EC 2.5.1.112: adenylate dimethylallyltransferase (ADP/ATP-dependent) EC 2.5.1.113: [CysO sulfur-carrier protein]-thiocarboxylate-dependent cysteine synthase EC 2.5.1.114: tRNAPhe (4-demethylwyosine37-C7) aminocarboxypropyltransferase EC 2.5.1.115: homogentisate phytyltransferase EC 2.5.1.116: homogentisate geranylgeranyltransferase EC 2.5.1.117: homogentisate solanesyltransferase EC 2.5.1.118: β-(isoxazolin-5-on-2-yl)-L-alanine synthase EC 2.5.1.119: β-(isoxazolin-5-on-4-yl)-L-alanine synthase EC 2.5.1.120: aminodeoxyfutalosine synthase EC 2.5.1.121: 5,10-dihydrophenazine-1-carboxylate 9-dimethylallyltransferase EC 2.5.1.122: 4-O-dimethylallyl-L-tyrosine synthase EC 2.5.1.123: flaviolin linalyltransferase EC 2.5.1.124: 6-linalyl-2-O,3-dimethylflaviolin synthase EC 2.5.1.125: 7-geranyloxy-5-hydroxy-2-methoxy-3-methylnaphthalene-1,4-dione synthase EC 2.5.1.126: norspermine synthase EC 2.5.1.127: caldopentamine synthase EC 2.5.1.128: N4-bis(aminopropyl)spermidine synthase EC 2.5.1.129: flavin prenyltransferase EC 2.5.1.130: 2-carboxy-1,4-naphthoquinone phytyltransferase EC 2.5.1.131: (4-{4-[2-(γ-L-glutamylamino)ethyl]phenoxymethyl}furan-2-yl)methanamine synthase EC 2.5.1.132: 3-deoxy-D-glycero-D-galacto-nonulopyranosonate 9-phosphate synthase EC 2.5.1.133: bacteriochlorophyll a synthase EC 2.5.1.134: cystathionine β-synthase (O-acetyl-L-serine) EC 2.5.1.135: validamine 7-phosphate valienyltransferase EC 2.5.1.136: 2-acylphloroglucinol 4-prenyltransferase EC 2.5.1.137: 2-acyl-4-prenylphloroglucinol 6-prenyltransferase EC 2.5.1.138: coumarin 8-geranyltransferase EC 2.5.1.139: umbelliferone 6-dimethylallyltransferase EC 2.5.1.140: N-(2-amino-2-carboxyethyl)-L-glutamate synthase EC 2.5.1.141: heme o synthase EC 2.5.1.142: nerylneryl diphosphate synthase EC 2.5.1.143: pyridinium-3,5-biscarboxylic acid mononucleotide synthase EC 2.5.1.144: S-sulfo-L-cysteine synthase (O-acetyl-L-serine-dependent) EC 2.5.1.145: phosphatidylglycerol—prolipoprotein diacylglyceryl transferase EC 2.5.1.146: 3-geranyl-3-[(Z)-2-isocyanoethenyl]indole synthase EC 2.5.1.147: 5-amino-6-(D-ribitylamino)uracil—L-tyrosine 4-hydroxyphenyl transferase EC 2.5.1.148: lycopaoctaene synthase EC 2.5.1.149: lycopene elongase/hydratase (flavuxanthin-forming) EC 2.5.1.150: lycopene elongase/hydratase (dihydrobisanhydrobacterioruberin-forming) EC 2.5.1.151: alkylcobalamin dealkylase EC 2.5.1.152: D-histidine 2-aminobutanoyltransferase EC 2.5.1.153: adenosine tuberculosinyltransferase
Sources: en.wikipedia.org
== Preceding viral infections == A number of different preceding viral infections have been reported, most commonly influenza A and B. The condition appears to be more prevalent during late fall, winter, and spring. Other virus infections that have been linked to BACM are those caused by Parainfluenza, Coxsackievirus, Adenovirus, Echovirus, and Mycoplasma pneumonia. Viral myositis after viral infections may also occur in adults, and viruses, such as COVID-19, have been reported as a rare cause of myositis.
=== Mechanism of toxicity in humans === After FIAU is converted to FIAU-TP, it is not only available to viral polymerase, in humans it can also be taken up into mitochondria and used by mitochondrial DNA polymerase γ (POLG). When FIAU is incorporated into mitochondrial DNA (mtDNA), it disrupts mtDNA replication, which leads to mtDNA depletion. With less mtDNA, cells can make fewer proteins for the electron transport chain, so oxidative phosphorylation fails. The consequences are lactic acidosis (shift to anaerobic metabolism) and microvascular steatosis (impaired fatty-acid oxidation), especially in the liver
== Experimental chemistry == Meitnerium is the first element on whose chemistry has not yet been investigated. Unambiguous determination of its chemical properties is yet to have been established due to the short half-lives of meitnerium isotopes and a limited number of likely volatile compounds that could be studied on a tiny scale. One of the few meitnerium compounds that are likely to be volatile enough is meitnerium hexafluoride MtF6, as its lighter homolog iridium hexafluoride (IrF6) is volatile above 60°C, so the analogous compound of meitnerium might also be volatile enough; a volatile octafluoride MtF8 might also be possible. For chemical studies on a transactinide, at least four atoms must be produced, the half-life of the isotope used must be ≥1 second, and the rate of production must be at least one atom per week. Even though the half-life of 278Mt, the most stable confirmed isotope, is 4.5 seconds, long enough for chemical studies, another obstacle is the need to increase the rate of production of meitnerium and allow experiments to carry on for weeks or months so that statistically significant results can be obtained. Separation and detection must be carried out continuously to separate out the meitnerium isotopes and have automated systems experiment on the gas-phase and solution chemistry of meitnerium, as the yields for heavier elements are predicted to be smaller than those for lighter elements; some of the separation techniques used for bohrium and hassium could be reused.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.